NBCC’s advocacy has resulted in more than $3.9 billion federal dollars for breast cancer research.
Breast cancer accounts for nearly a quarter of all cancers in women worldwide.
The DOD BCRP was created as a result of NBCC’s “$300 Million More” campaign to increase federal funding for breast cancer research.
The National Breast Cancer Coalition is proud to announce bipartisan support for a bill to waive onerous health care waiting periods for those with metastatic breast cancer.
FDA ODAC Meeting Recap, Watch NBCC Exclusive Webinars, Keep Up With Our Cancer History Project Contributor Page, And More!
We all want new treatments to “work” for breast cancer patients. For the National Breast Cancer Coalition (NBCC), that means the investigational therapy will significantly prolong overall survival (OS) without adverse impact on quality of life. We expect that the evidence of that benefit will be shown by well-designed, well-conducted prospective randomized clinical trials, sufficiently designed to support that result. Unfortunately, that has not been the case with TECENTRIQ® (atezolizumab) in first-line treatment of advanced or metastatic triple-negative breast cancer (TNBC).
NBCC is excited to announce that we will hold our 2021 Virtual Advocate Leadership Summit on May 13th-15th, followed by Lobby Day on May 18th. Join with fellow survivors, advocates, and members of the breast cancer community, who are lending their voice and transforming breast cancer research and public policy, and ensuring quality healthcare for all.